A new data standard for multiple sclerosis has been released by the Clinical Data Interchange Standards Consortium.
A new data standard for multiple sclerosis (MS) has been released by the Clinical Data Interchange Standards Consortium (CDISC), the leading global standards organization for clinical research. When used together with the foundational CDISC clinical data standard, this therapeutic area standard allows clinical research data from multiple MS trials to be grouped for reporting, analysis, and regulatory submissions.
The standard is the result of work from organizations across the globe. Led by the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a Critical Path Institute (C-Path) consortium, the effort drew on the ‘common data elements’ developed for MS through the National Institute of Neurological Disorders and Stroke (NINDS). MSOAC members with clinical expertise in MS connected with CDISC teams in the standardization process designed by the Coalition for Accelerating Standards and Therapies (CFAST) initiative. In the CFAST standardization process, standards developers work closely with clinical experts on definitions and scoping from the beginning.
Like other open CDISC data standards, the new MS standard is freely available (http://www.cdisc.org/therapeutic#MS). “This new tool is more than another resource for the MS research community, ” indicated Dr. Timothy Coetzee, Chief Advocacy, Services and Research Officer at the National MS Society. “This new MS standard signals a commitment to ensure that data does not remain in silos. By standardizing data we expect that research will move us faster toward our goal of a world free of MS.”
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.